---
title: "Cranoluten"
canonical_url: https://peptidelibrary.app/library/cranoluten
description: "Peptide preparation extracted from brain tissue and sold as a central nervous system bioregulator in the Khavinson tradition. It is a complex of low-molecular-weight peptides rather than a single defined molecule, so no specific sequence or mechanism can be assigned and batch composition is not standardised. No study of Cranoluten itself is indexed in PubMed; the studies cited here are class-level work on short peptide bioregulators. It is not FDA-approved."
updated: 2026-11-07
publisher: Peptide Library
notice: "Research and educational use only. Not medical advice."
---

# Cranoluten

Cranoluten (also called Brain bioregulator) is a khavinson bioregulator. Cranoluten is a peptide preparation extracted from brain tissue and marketed in the Khavinson tradition for central nervous system support.

Peptide preparation extracted from brain tissue and sold as a central nervous system bioregulator in the Khavinson tradition. It is a complex of low-molecular-weight peptides rather than a single defined molecule, so no specific sequence or mechanism can be assigned and batch composition is not standardised. No study of Cranoluten itself is indexed in PubMed; the studies cited here are class-level work on short peptide bioregulators. It is not FDA-approved.

Also known as: Brain bioregulator.

Categories: Cognitive, Experimental.

## Classification

- Type: Khavinson bioregulator / research
- Mechanism class: Short Peptide Bioregulator
- Development stage: Research only
- Regulatory class: Research compound, not FDA-approved

## Mechanism

Cranoluten is a peptide preparation extracted from brain tissue and marketed in the Khavinson tradition for central nervous system support. It is a complex of low-molecular-weight peptides rather than a single defined molecule, so no specific sequence, receptor or signalling pathway can be assigned to it, and batch composition is not standardised the way a single-entity drug would be. The proposed mechanism follows the series hypothesis that tissue-derived peptides act preferentially on the tissue they came from by influencing gene expression. No controlled human trials of this preparation have been published.

Targets: CNS (proposed).

Origin: Synthetic short peptide bioregulator.

## Properties

- Molecular formula: C15H27N3O8
- Molecular weight: 393.39 g/mol
- CAS number: 169772-06-9
- Half-life: Not established

## Evidence

- Evidence level: Insufficient Evidence
- Highest documented: None documented
- Human trials: 0
- Controlled human trials: 0
- Preclinical sources: 0

No human dose is established for this compound.

Each step shows whether the sources Peptide Library has reviewed include that kind of research. Counts are reviewed sources, not every study ever published. Reviews and programme summaries that describe human use are shown as "reported", not as trials, and registered trials without published results are listed but not counted. A higher step means research has progressed further; it does not mean a compound works better or is safer. Compounds whose evidence has not been reviewed yet show "Not reviewed" instead of a guess.

### Studies

1. Tissue-specific effects of peptides. Bull Exp Biol Med. 2001. 2001. Preclinical: in vitro (cells or tissue). Population: Explants of rat brain cortex, subcortical structures, liver and thymus in organotypic culture. Cortagen, Epithalon, Livagen and Vilon each stimulated growth of explants from the tissue their source peptide complex came from. Cortagen, the peptide in this study linked to brain cortex, is a different synthetic peptide; Cranoluten itself was not tested. Research on a related compound, not this one. Limitations: Studied an analog, not Cranoluten itself; Lab or animal research: not evidence of a human effect or dose. [Source](https://pubmed.ncbi.nlm.nih.gov/11713572/)

## Safety

Side effects: Not well characterized.

Risks: Research-only.

Human safety basis: No controlled human safety data

Key limitations: No established human dosage.; No controlled human trial results in the reviewed sources.; Not approved by the FDA for any use..

## Regulatory status

Cranoluten is not an FDA-approved product. It is sold for laboratory research and has no approved medical use.

- FDA status: Not Approved
- Availability: Research-Only

## Frequently asked questions

### What is Cranoluten?

Peptide preparation extracted from brain tissue and sold as a central nervous system bioregulator in the Khavinson tradition. It is a complex of low-molecular-weight peptides rather than a single defined molecule, so no specific sequence or mechanism can be assigned and batch composition is not standardised. No study of Cranoluten itself is indexed in PubMed; the studies cited here are class-level work on short peptide bioregulators. It is not FDA-approved.

### How does Cranoluten work?

Cranoluten is a peptide preparation extracted from brain tissue and marketed in the Khavinson tradition for central nervous system support. It is a complex of low-molecular-weight peptides rather than a single defined molecule, so no specific sequence, receptor or signalling pathway can be assigned to it, and batch composition is not standardised the way a single-entity drug would be.

### Is Cranoluten FDA approved?

No. Cranoluten is not approved by the FDA for any indication and is categorised as research-only. It has not been reviewed for safety or efficacy as a medicine, and published research should be read as investigation rather than established use.

### What peptides are similar to Cranoluten?

Compounds most often compared with Cranoluten include Bonomarlot, Bronchogen, Cardiogen and Cartalax. They are grouped by shared mechanism or research area rather than by equivalence, and their regulatory status and evidence base differ.

## References

- [Class-level evidence — Khavinson VK. Peptides and Ageing. Neuro Endocrinol Lett, 2002](https://pubmed.ncbi.nlm.nih.gov/12374906/)
- [Class-level evidence — Tissue-specific effects of peptides. Bull Exp Biol Med, 2001](https://pubmed.ncbi.nlm.nih.gov/11713572/)
- [Class-level evidence — Peptide bioregulation of aging: results and prospects — Biogerontology, 2010](https://pubmed.ncbi.nlm.nih.gov/19830585/)
- [Class-level evidence — Mechanisms underlying geroprotective effects of peptides — Bull Exp Biol Med, 2002](https://pubmed.ncbi.nlm.nih.gov/12170291/)
- [Class-level evidence — Epigenetic mechanisms of peptide-driven regulation and neuroprotective protein FKBP1b — Mol Biol (Mosk), 2019](https://pubmed.ncbi.nlm.nih.gov/31099784/)
